NPC(SH:600713) Zheng Quan Zhi Xing·2025-06-24 17:13Core Viewpoint - The announcement details the issuance and terms of the convertible bond "NanYao Convertible Bond" by Nanjing Pharmaceutical Co., Ltd, including its conversion price, issuance scale, and relevant procedures for bondholders [1][2][3]. Group 1: Issuance Overview - The convertible bond code is 110098 and the bond name is "NanYao Convertible Bond" [1]. - The total issuance amount is 1,081.49 million RMB, with each bond having a face value of 100 RMB [2]. - The bond has a term of 6 years, from December 25, 2024, to December 24, 2030 [2]. Group 2: Conversion Terms - The conversion price is set at 5.12 RMB per share [2][4]. - The conversion period starts from July 1, 2025, and ends on December 24, 2030 [2][3]. - The bond has a tiered interest rate structure, starting at 0.20% in the first year and increasing to 2.00% in the sixth year [2]. Group 3: Conversion Procedures - Bondholders can apply for conversion during the specified conversion period on trading days [3]. - The conversion process includes a mechanism for handling fractional shares and the calculation of the actual convertible bond quantity [3][4]. - Newly converted shares will have the same rights as existing shares [4]. Group 4: Adjustment of Conversion Price - The initial conversion price was set at 5.29 RMB per share, which has been adjusted to 5.12 RMB due to a cash dividend distribution [5][6]. - The conversion price can be adjusted based on various corporate actions, including stock dividends and cash dividends [6][8]. - The company has the right to propose downward adjustments to the conversion price if the stock price falls below certain thresholds [8][9]. Group 5: Redemption and Sale Rights - The company may redeem the unconverted bonds at 108% of the face value within five trading days after maturity [10]. - Bondholders have the right to sell back their bonds to the company if the stock price falls below 70% of the conversion price during the last two interest years [10][12]. - Additional sale rights are available if there are significant changes in the use of raised funds [12].